A Multicentre Evaluation of Dosiomics Features Reproducibility, Stability and Sensitivity.

dose distribution texture analysis dosiomics multicentric study radiation dosimetry radiotherapy reproducibility sensitivity stability

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Jul 2021
Historique:
received: 30 06 2021
revised: 28 07 2021
accepted: 29 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

Dosiomics is a texture analysis method to produce dose features that encode the spatial 3D distribution of radiotherapy dose. Dosiomic studies, in a multicentre setting, require assessing the features' stability to dose calculation settings and the features' capability in distinguishing different dose distributions. Dose distributions were generated by eight Italian centres on a shared image dataset acquired on a dedicated phantom. Treatment planning protocols, in terms of planning target volume coverage and dose-volume constraints to the organs at risk, were shared among the centres to produce comparable dose distributions for measuring reproducibility/stability and sensitivity of dosiomic features. In addition, coefficient of variation (CV) was employed to evaluate the dosiomic features' variation. We extracted 38,160 features from 30 different dose distributions from six regions of interest, grouped by four features' families. A selected group of features (CV < 3 for the reproducibility/stability studies, CV > 1 for the sensitivity studies) were identified to support future multicentre studies, assuring both stable features when dose distributions variation is minimal and sensitive features when dose distribution variations need to be clearly identified. Dosiomic is a promising tool that could support multicentre studies, especially for predictive models, and encode the spatial and statistical characteristics of the 3D dose distribution.

Identifiants

pubmed: 34359737
pii: cancers13153835
doi: 10.3390/cancers13153835
pmc: PMC8345157
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : ERA-NET ERA PerMed / FRRB grant agreement
ID : ERAPERMED2018-244

Références

Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):71-8
pubmed: 2032898
Phys Med Biol. 2020 Sep 28;65(19):195015
pubmed: 32235058
Diagnostics (Basel). 2021 Apr 10;11(4):
pubmed: 33920221
PLoS One. 2016 Jul 28;11(7):e0159984
pubmed: 27467882
J Med Imaging (Bellingham). 2020 Jan;7(1):014504
pubmed: 32118090
Phys Med. 2015 Jun;31(4):333-51
pubmed: 25840619
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Ann Oncol. 2020 Jul;31(7):912-920
pubmed: 32304748
Oral Oncol. 2020 May;104:104625
pubmed: 32151995
Phys Med. 2021 Apr;84:186-191
pubmed: 33901863
Diagnostics (Basel). 2020 Sep 17;10(9):
pubmed: 32957690
Phys Med Biol. 2020 Sep 29;65(19):195012
pubmed: 32575082
Cancers (Basel). 2021 May 11;13(10):
pubmed: 34064923
PLoS One. 2014 Jul 15;9(7):e102107
pubmed: 25025374
Cancers (Basel). 2021 Jan 18;13(2):
pubmed: 33477723
Sci Rep. 2016 Mar 24;6:23428
pubmed: 27009765
Radiother Oncol. 2018 Dec;129(3):548-553
pubmed: 30177372
Phys Med. 2013 May;29(3):295-303
pubmed: 22583979
Med Phys. 2019 Mar;46(3):1512-1518
pubmed: 30629299
Radiother Oncol. 2020 Dec;153:26-33
pubmed: 32987045
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1143-1158
pubmed: 30170872
Artif Intell Med. 2019 May;96:145-153
pubmed: 30292538
Sci Rep. 2017 Apr 3;7(1):588
pubmed: 28373718
Front Oncol. 2020 Apr 21;10:490
pubmed: 32373520
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2638-2655
pubmed: 31240330
Front Oncol. 2020 Jan 31;9:1500
pubmed: 32076596
Strahlenther Onkol. 2020 Oct;196(10):879-887
pubmed: 32367456
J Clin Epidemiol. 2011 Jan;64(1):96-106
pubmed: 21130355
Phys Med. 2020 Sep;77:30-35
pubmed: 32768918
Front Oncol. 2018 Mar 05;8:35
pubmed: 29556480
Med Phys. 2021 Apr;48(4):1781-1791
pubmed: 33576510

Auteurs

Lorenzo Placidi (L)

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Roma, Italy.

Eliana Gioscio (E)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.

Cristina Garibaldi (C)

IEO, Unit of Radiation Research, European Institute of Oncology IRCCS, 20141 Milan, Italy.

Tiziana Rancati (T)

Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.

Annarita Fanizzi (A)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.

Davide Maestri (D)

Fondazione CNAO, Strada Campeggi 53, 27100 Pavia, Italy.

Raffaella Massafra (R)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.

Enrico Menghi (E)

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Alfredo Mirandola (A)

Fondazione CNAO, Strada Campeggi 53, 27100 Pavia, Italy.

Giacomo Reggiori (G)

Medical Physics Service, Radiation Oncology Department, Humanitas Clinical and Research Hospital, 20089 Rozzano-Milan, Italy.

Roberto Sghedoni (R)

Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Pasquale Tamborra (P)

I.R.C.C.S. Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.

Stefania Comi (S)

IEO, Unit of Medical Physics, European Institute of Oncology IRCCS, 20141 Milan, Italy.

Jacopo Lenkowicz (J)

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Roma, Italy.

Luca Boldrini (L)

Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Roma, Italy.

Michele Avanzo (M)

Medical Physics Department, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.

Classifications MeSH